Key result
Milrinone exhibited significantly enhanced vasorelaxation in small porcine pulmonary arteries precontracted with epinephrine or norepinephrine compared to phenylephrine or U46619.
Why the study?
Does milrinone improve vasorelaxation in porcine pulmonary vascular rings precontracted with catecholamines?
Does milrinone improve vasorelaxation in porcine pulmonary vascular rings precontracted with catecholamines?
Milrinone exhibits enhanced vasodilator effects in small pulmonary arteries when combined with beta-adrenoreceptor agonists, suggesting potential benefit in ventricular dysfunction with increased pulmonary vascular resistance.
Hypothesis-generating for milrinone-catecholamine synergy in pulmonary hypertension; leaves open human translation.
UNLABELLED: Beta-adrenergic agonists (e.g., epinephrine [E] and norepinephrine [NE]) and phosphodiesterase-III inhibitors (e.g., milrinone) are often used in combination to augment ventricular function in the perioperative period. In the myocardium, milrinone acts synergistically with beta-adrenergic agonists to increase contractility. However, the potential interaction between catecholamines with combined alpha- and beta-adrenergic activity and milrinone in the pulmonary circulation has not been determined. We evaluated the vasodilatory effects of milrinone and nitroglycerine on large elastic and small muscular porcine pulmonary vascular rings precontracted with catecholamines with beta-adrenergic agonist activity (E and NE), the alpha-adrenergic agonist phenylephrine, and a nonadrenergic agonist, the thromboxane analog U46619. In small pulmonary arteries, the vasorelaxation with milrinone was significantly enhanced in rings precontracted with E or NE compared with those precontracted with phenylephrine or U46619. However, in large pulmonary arteries, the vasorelaxation with milrinone was similar in all vessel rings and was not influenced by the agonist used to induce precontraction. In marked contrast, the vasorelaxant responses to nitroglycerine were not altered by the specific agonist used for precontraction in either small or large pulmonary vascular rings. Thus, the pulmonary vascular effects of milrinone are enhanced when combined with drugs with beta-adrenoreceptor agonist activity. The vasodilatory interactions exhibited by phosphodiesterase-III inhibitors and the catecholamines NE and E suggest that their combined use might be beneficial in circumstances in which ventricular dysfunction and increased pulmonary vascular resistance occur. IMPLICATIONS: This study demonstrated that milrinone had enhanced vasodilator effects when combined with drugs with beta-adrenoreceptor agonist activity in small pulmonary artery segments removed from pigs.
No takes yet. Share an insight, caveat, or question.
Jhaveri et al. (2004) studied this question. Milrinone vs. Nitroglycerine was evaluated on Vasodilatory effects (vasorelaxation). Milrinone exhibited significantly enhanced vasorelaxation in small porcine pulmonary arteries precontracted with epinephrine or norepinephrine compared to phenylephrine or U46619.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: